Highlights

  • Mayne Pharma has received a payment covering legal costs following a collapsed takeover attempt.
  • A new chief financial officer starts in August 2026, ending a lengthy vacancy.
  • Half-year revenue held broadly steady while gross margin improved.
  • Convertible notes are due for repayment before the end of 2026.
  • A separate damages claim against the former bidder continues, with no amount yet disclosed.

Few ASX-listed companies have been as consumed by a single corporate event as Mayne Pharma. In early 2025, the Adelaide-based specialty pharmaceutical group agreed to be acquired by a US private-equity backed buyer. What followed was a purported termination of the deal, a contested court case, a government intervention on national interest grounds, and a company left listed and independent, holding the legal bill. Part of that bill has now been recovered, and a long-vacant finance role has been filled.

What Has Happened

Mayne pursued the matter through the New South Wales Supreme Court after the buyer purported to terminate the agreement, alleging a material adverse change. The court found in Mayne's favour and ordered the buyer to pay Mayne's litigation costs. The Australian Treasurer separately blocked the takeover on national interest grounds in late 2025, and the buyer served its own termination notice shortly after, which Mayne rejected as invalid. An appeal followed, and Mayne has since launched separate proceedings seeking damages from the would-be buyer and related parties, though no damages figure has been disclosed.

In June 2026, the company confirmed it had received payment covering the court-ordered legal costs. Weeks later, it announced a new chief financial officer, starting 1 August 2026, ending a vacancy of several months.

Understanding the Company

Mayne Pharma commercialises branded pharmaceutical products across three segments: women's health, dermatology and an international division that includes contract manufacturing from its South Australian facility. In recent years the company shifted away from lower-margin generic medicines toward a branded portfolio, lifting gross margin meaningfully. To support that shift, it has launched a direct-to-patient distribution model in the United States and expanded local manufacturing investment.

Financial and Operational Position

For the half year to December 2025, revenue was little changed at around A$212 million, while gross margin improved. Underlying earnings before interest, tax, depreciation and amortisation declined modestly, and the statutory loss narrowed compared with the prior period, though scheme-related legal costs were a significant drag on both cash flow and the result. Cash and marketable securities fell over the half, partly reflecting those legal costs. Convertible notes issued in 2022 remain outstanding, maturing at the end of 2026, at a conversion price well above the current share price, making cash repayment the likely outcome.

Why the Development Matters

The recovered legal costs are not transformative against the size of the business, but they offset a meaningful share of the cash spent on the collapsed deal, and arrive in the same year the convertible notes fall due. The new finance appointment addresses a structural gap during a period that includes ongoing litigation, a new distribution model and the note maturity. Both developments remove sources of uncertainty rather than changing the underlying earnings power of the business, and the fact that costs were successfully recovered from a US counterparty may be a relevant consideration in weighing the ongoing damages claim.

Risks and Challenges

The most immediate risk is the approaching debt maturity, with the notes due for repayment in cash given the conversion price is well above the current share price; available cash makes this manageable but limits flexibility. Ongoing litigation could absorb cash and management attention for an extended period with no certainty of a further recovery. Segment performance has also been mixed, with one division's earnings contribution declining sharply even as overall margins improved, and there has been considerable turnover among directors and senior management over the past year.

Conclusion

Mayne Pharma enters the second half of 2026 having been vindicated in court but still without the transaction it originally agreed to, and trading well below the price a bidder once offered. The cost recovery and CFO appointment do not change underlying earnings power, but they close two items that had made the business harder to assess. What remains is proving that recent margin gains are durable and that the year-end debt maturity can be cleared without diluting shareholders.